Aug 6, 2019 by Brian Orelli, PhDBioMarin's Roller Coaster ContinuesLong-term investors need to learn to stomach the ride.
Aug 6, 2019 by Brian Orelli, PhDEmergent BioSolutions Looks to the Second Half for GrowthThe bioterrorism expert still has some negotiating with the government to do.
Aug 6, 2019 by Brian Orelli, PhDVertex Has "Significant Financial Firepower"A dominant cystic fibrosis franchise drives cash flow.
Aug 5, 2019 by Brian Orelli, PhDExelixis Hits Blockbuster StatusThe biotech needed help from some friends to get there.
Aug 1, 2019 by Brian Orelli, PhDHere’s Why Insmed Fell Hard TodayAfter a solid second quarter, investors in the biopharmaceutical company were left to wonder about management’s tepid growth forecast.
Jul 31, 2019 by Brian Orelli, PhDHere’s Why Castlight Health's Shares Got Cut in Half TodayThe health navigation expert had a rough second quarter, and it isn't clear when things will turn around.
Jul 30, 2019 by Brian Orelli, PhDBiogen Hedged Its Bet and Won BigThe biotech had $4.3 billion in sales at risk.
Jul 26, 2019 by Brian Orelli, PhDAlkermes Bounces Back -- but Not EnoughA slow launch has investors worried.
Jul 24, 2019 by Brian Orelli, PhDHere's Why Genomic Health Jumped Almost 15% TodayIt had nothing to do with the underlying value of the company.
Jul 24, 2019 by Brian Orelli, PhDBiogen Raises Guidance as It Looks to the Pipeline for GrowthCutting expenses and repurchasing shares will only get the drugmaker so far.
Jul 18, 2019 by Brian Orelli, PhDSeattle Genetics Hits Its Second Growth PhaseThere's potential for more with a pipeline of drugs in development.
Jul 17, 2019 by Brian Orelli, PhDHere's Why Seattle Genetics Rocketed Higher TodaySales growth of the biotech's blood cancer drug Adcetris rebounded.
Jul 12, 2019 by Brian Orelli, PhDHere's Why Johnson & Johnson Dropped 4% TodayThe healthcare giant is reportedly under investigation by the Department of Justice.
Jul 11, 2019 by Brian Orelli, PhDHere's Why Aimmune Therapeutics Fell 7% TodayThe Institute for Clinical and Economic Review questions the short-term risks of the biotech's drug.
Jul 11, 2019 by Brian Orelli, PhDHere's Why Sangamo Therapeutics Jumped 23% in JuneThe biotech's gene therapy to treat hemophilia A looks promising.
Jul 9, 2019 by Brian Orelli, PhDHere's Why Intrexon Jumped 58% in JuneThe biotech is getting into the cannabinoids business.
Jul 2, 2019 by Brian Orelli, PhD3 Biotechs That Have Doubled This Year (Acquisition Next?)Good news has a way of attracting suitors.
Jun 27, 2019 by Brian Orelli, PhDHere's Why Dova Pharmaceuticals Stock Jumped Higher TodayThe drugmaker's Doptelet therapy just received an expanded approval.
